Literature DB >> 12632815

Combined effects of chronic hepatitis virus infections and substance-use habits on chronic liver diseases in Taiwanese aborigines.

Hans-Hsienhong Lin1, Li-Yu Wang, Cheng-Kuang Shaw, Mu-Liang Cheng, Wen-Kuan Chung, Hsin-Jung Chiang, Teng-Yi Lin, Chien-Jen Chen.   

Abstract

BACKGROUND AND
PURPOSE: Chronic liver disease (CLD) is a major cause of death in Taiwanese aborigines. The roles of substance-use habits and hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in the development of CLD are not well understood in this indigenous population.
METHODS: A hospital-based, case-control study of 79 consecutive CLD patients and 107 non-CLD controls was performed. Serostatus of hepatitis B surface antigen (HBsAg) and antibodies against hepatitis C virus (anti-HCV) were determined in all subjects. Each subject completed an epidemiologic questionnaire about the risk factors of CLD.
RESULTS: Atayal ethnicity, alcohol drinking, cigarette smoking, betel quid chewing, seropositivity of HBsAg and anti-HCV antibodies were associated with a significantly elevated CLD risk. In the combinatory analyses of HBsAg serostatus and substance-use habits, HBsAg-positive substance users had the highest CLD risk, followed by HBsAg-positive non-users, HBsAg-negative users, and HBsAg-negative non-users. Similarly, anti-HCV-positive alcohol drinkers and betel quid chewers had greater CLD risks than other groups. The multivariate-adjusted odds ratios (ORs) for males, Atayal ethnicity and seropositivity of HBsAg and anti-HCV were significantly elevated. There was a biologic gradient in the risk of developing CLD associated with the number of substance-use habits. The multivariate-adjusted ORs were 4.7 (95% confidence interval [CI], 1.3-16.8) and 7.9 (95% CI, 2.1-30.4) for subjects with 1-2 and 3 habits, respectively, compared to subjects with no habit.
CONCLUSION: Our data suggest that chronic HBV and HCV infections, alcohol drinking, cigarette smoking, and betel quid chewing play important roles in the development of CLD in Taiwanese aborigines.

Entities:  

Mesh:

Year:  2002        PMID: 12632815

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  7 in total

1.  Uncovering the relation between betel quid chewing and cigarette smoking in Taiwan.

Authors:  C P Wen; S P Tsai; T Y Cheng; C-J Chen; D T Levy; H-J Yang; M P Eriksen
Journal:  Tob Control       Date:  2005-06       Impact factor: 7.552

2.  Antioxidative status of patients with alcoholic liver disease in southeastern Taiwan.

Authors:  Ya-Ling Chen; Li-Ju Chen; Ming-Jong Bair; Mei-Lan Yao; Hsiang-Chi Peng; Sien-Sing Yang; Suh-Ching Yang
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

Review 3.  Risk of liver disease in areca nut habitual: A systematic review.

Authors:  Suwarna B Dangore Khasbage; Rahul R Bhowate; Nazli Khatib
Journal:  J Oral Maxillofac Pathol       Date:  2022-03-31

4.  The risk of cirrhosis in non-alcohol drinkers is greater in female than male betel nut chewers.

Authors:  Yu-Hua Chu; Lee Wang; Pei-Chieh Ko; Shou-Jen Lan; Yung-Po Liaw
Journal:  Oncotarget       Date:  2018-01-03

5.  Prevalence and determinants of biochemical dysfunction of the liver in Atayal Aboriginal community of Taiwan: is betel nut chewing a risk factor?

Authors:  Ching-Feng Lin; Tun-Jen Shiau; Ying-Chin Ko; Ping-Ho Chen; Jung-Der Wang
Journal:  BMC Gastroenterol       Date:  2008-04-27       Impact factor: 3.067

6.  Betel Chewing and Nonalcoholic Steatohepatitis.

Authors:  Wissam Bleibel; Saad Saleem
Journal:  Cureus       Date:  2018-07-08

7.  Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-By-Village Screening and Linking to Outreach Hepatology Care.

Authors:  Hui-Min Tien; Tai-Chung Cheng; Hsiao-Chu Lien; Kuei-Fei Yang; Cherng-Gueih Shy; Yu-Ling Chen; Nien-Tzu Hsu; Sheng-Nan Lu; Jing-Houng Wang
Journal:  Int J Environ Res Public Health       Date:  2022-03-10       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.